|
|
T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million
|
|
|
T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region
|
|
|
T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference
|
|
|
T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
|
|
|
T2 Biosystems Announces Second Quarter 2022 Financial Results
|
|
|
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus
|
|
|
T2 Biosystems Reports Granting of Inducement Awards
|
|
|
T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022
|
|
|
T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference
|
|
|
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
|
